|
1
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bechis SK, Carroll PR and Cooperberg MR:
Impact of age at diagnosis on prostate cancer treatment and
survival. J Clin Oncol. 29:235–241. 2011. View Article : Google Scholar :
|
|
3
|
Chen CD, Welsbie DS, Tran C, Baek SH, Chen
R, Vessella R, Rosenfeld MG and Sawyers CL: Molecular determinants
of resistance to antiandrogen therapy. Nat Med. 10:33–39. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shahinian VB, Kuo YF, Freeman JL and
Goodwin JS: Risk of fracture after androgen deprivation for
prostate cancer. N Engl J Med. 352:154–164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X
and Song Y: Overexpression of LSD1 promotes proliferation,
migration and invasion in non-small cell lung cancer. PloS One.
7:e350652012. View Article : Google Scholar
|
|
6
|
Zhao ZK, Dong P, Gu J, Chen L, Zhuang M,
Lu WJ, Wang DR and Liu YB: Overexpression of LSD1 in hepatocellular
carcinoma: A latent target for the diagnosis and therapy of
hepatoma. Tumor Biol. 34:173–180. 2013. View Article : Google Scholar
|
|
7
|
Qin Y, Zhu W, Xu W, Zhang B, Shi S, Ji S,
Liu J, Long J, Liu C, Liu L, et al: LSD1 sustains pancreatic cancer
growth via maintaining HIF1α-dependent glycolytic process. Cancer
Lett. 347:225–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kauffman EC, Robinson BD, Downes MJ,
Powell LG, Lee MM, Scherr DS, Gudas LJ and Mongan NP: Role of
androgen receptor and associated lysine-demethylase coregulators,
LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Mol Carcinog. 50:931–944. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Metzger E, Wissmann M, Yin N, Müller JM,
Schneider R, Peters AH, Günther T, Buettner R and Schüle R: LSD1
demethylates repressive histone marks to promote
androgen-receptor-dependent transcription. Nature. 437:436–439.
2005.PubMed/NCBI
|
|
10
|
Kahl P, Gullotti L, Heukamp LC, Wolf S,
Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J,
Metzger E, et al: Androgen receptor coactivators lysine-specific
histone demethylase 1 and four and a half LIM domain protein 2
predict risk of prostate cancer recurrence. Cancer Res.
66:11341–11347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seligson DB, Horvath S, Shi T, Yu H, Tze
S, Grunstein M and Kurdistani SK: Global histone modification
patterns predict risk of prostate cancer recurrence. Nature.
435:1262–1266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Natile G and Coluccia M: Current status of
trans-platinum compounds in cancer therapy. Coord Chem Rev.
216:383–410. 2001. View Article : Google Scholar
|
|
13
|
Miller RP, Tadagavadi RK, Ramesh G and
Reeves WB: Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel).
2:2490–2518. 2010. View Article : Google Scholar
|
|
14
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar
|
|
15
|
Gumulec J, Balvan J, Sztalmachova M,
Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K,
Ruttkay-Nedecky B, Babula P, et al: Cisplatin-resistant prostate
cancer model: Differences in antioxidant system, apoptosis and cell
cycle. Int J Oncol. 44:923–933. 2014.
|
|
16
|
Rose PG, Sill MW, McMeekin DS, Ahmed A,
Salani R, Yamada SD, Wolfson AH, Fusco N and Fracasso PM: A phase I
study of concurrent weekly topotecan and cisplatin chemotherapy
with whole pelvic radiation therapy in locally advanced cervical
cancer: A gynecologic oncology group study. Gynecol Oncol.
125:158–162. 2012. View Article : Google Scholar
|
|
17
|
Stordal B, Hamon M, McEneaney V, Roche S,
Gillet JP, O'Leary JJ, Gottesman M and Clynes M: Resistance to
paclitaxel in a cisplatin-resistant ovarian cancer cell line is
mediated by P-glycoprotein. PloS One. 7:e407172012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li QQ, Wang G, Reed E, Huang L and Cuff
CF: Evaluation of cisplatin in combination with β-elemene as a
regimen for prostate cancer chemotherapy. Basic Clin Pharmacol
Toxicol. 107:868–876. 2010.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Jin F, Irshad S, Yu W, Belakavadi M,
Chekmareva M, Ittmann MM, Abate-Shen C and Fondell JD: ERK and AKT
signaling drive MED1 overexpression in prostate cancer in
association with elevated proliferation and tumorigenicity. Mol
Cancer Res. 11:736–747. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rick FG, Schally AV, Szalontay L, Block
NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S and Seitz
S: Antagonists of growth hormone-releasing hormone inhibit growth
of androgen-independent prostate cancer through inactivation of ERK
and Akt kinases. Proc Natl Acad Sci USA. 109:1655–1660. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harashima N, Inao T, Imamura R, Okano S,
Suda T and Harada M: Roles of the PI3K/Akt pathway and autophagy in
TLR3 signaling-induced apoptosis and growth arrest of human
prostate cancer cells. Cancer Immunol Immunother. 61:667–676. 2012.
View Article : Google Scholar
|
|
23
|
Leivonen SK and Kähäri VM: Transforming
growth factor-beta signaling in cancer invasion and metastasis. Int
J Cancer. 121:2119–2124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nicholson B and Theodorescu D:
Angiogenesis and prostate cancer tumor growth. J Cell Biochem.
91:125–150. 2004. View Article : Google Scholar
|
|
25
|
Wikström P, Damber J and Bergh A: Role of
transforming growth factor-beta1 in prostate cancer. Microsc Res
Tech. 52:411–419. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Denmeade SR and Isaacs JT: A history of
prostate cancer treatment. Nat Rev Cancer. 2:389–396. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kashyap V, Ahmad S, Nilsson EM, Helczynski
L, Kenna S, Persson JL, Gudas LJ and Mongan NP: The lysine specific
demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate
cancer. Mol Oncol. 7:555–566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kinkade CW, Castillo-Martin M, Puzio-Kuter
A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL,
Cordon-Cardo C and Abate-Shen C: Targeting AKT/mTOR and ERK MAPK
signaling inhibits hormone-refractory prostate cancer in a
preclinical mouse model. J Clin Invest. 118:3051–3064.
2008.PubMed/NCBI
|
|
31
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Danielpour D: Functions and regulation of
transforming growth factor-beta (TGF-beta) in the prostate. Eur J
Cancer. 41:846–857. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
ten Dijke P and Hill CS: New insights into
TGF-beta-Smad signalling. Trends Biochem Sci. 29:265–273. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tuxhorn JA, McAlhany SJ, Yang F, Dang TD
and Rowley DR: Inhibition of transforming growth factor-beta
activity decreases angiogenesis in a human prostate cancer-reactive
stroma xenograft model. Cancer Res. 62:6021–6025. 2002.PubMed/NCBI
|
|
35
|
Donkor MK, Sarkar A, Savage PA, Franklin
RA, Johnson LK, Jungbluth AA, Allison JP and Li MO: T cell
surveillance of oncogene-induced prostate cancer is impeded by T
cell-derived TGF-β1 cytokine. Immunity. 35:123–134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Micalizzi DS, Farabaugh SM and Ford HL:
Epithelial-mesenchymal transition in cancer: Parallels between
normal development and tumor progression. J Mammary Gland Biol
Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kirsch M, Schackert G and Black PM:
Angiogenesis, metastasis, and endogenous inhibition. J Neurooncol.
50:173–180. 2000. View Article : Google Scholar
|
|
38
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pàmies P: E-cadherin-guided migration. Nat
Mater. 13:6642014. View
Article : Google Scholar
|
|
40
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Muraki C, Ohga N, Hida Y, Nishihara H,
Kato Y, Tsuchiya K, Matsuda K, Totsuka Y, Shindoh M and Hida K:
Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor
endothelial and vascular progenitor cells. Int J Cancer. 130:59–70.
2012. View Article : Google Scholar
|
